Evidence map›Paper›PMID 34288348›Full record

ArticleEMBO reports2021

MiR-342 controls Mycobacterium tuberculosis susceptibility by modulating inflammation and cell death.

Beibei Fu, Xiaoyuan Lin, Shun Tan, Rui Zhang, Weiwei Xue, Haiwei Zhang, Shanfu Zhang, Qingting Zhao, Yu Wang, Kelly Feldman and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in EMBO reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Beibei FuSchool of Life Sciences, Chongqing University, Chongqing, China.
Xiaoyuan LinSchool of Life Sciences, Chongqing University, Chongqing, China.
Shun TanChongqing Public Health Medical Center, Chongqing, China.
Rui ZhangDepartment of Respiratory Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Weiwei XueSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, China.
Haiwei ZhangChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
Shanfu ZhangSchool of Life Sciences, Chongqing University, Chongqing, China.
Qingting ZhaoSchool of Life Sciences, Chongqing University, Chongqing, China.
Yu WangTechnical Center of Chongqing Customs, Chongqing, China.
Kelly FeldmanDepartment of Molecular and Cell Biology, University of California, Berkeley, CA, USA.
Lei ShiSchool of Life Sciences, Chongqing University, Chongqing, China.
Shaolin ZhangSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, China.
Weiqi NianChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
Krishna Chaitanya PavaniDepartment of Nutrition, Genetics and Ethology, Ghent University, Merelbeke, Belgium.
Zhifeng LiSchool of Life Sciences, Chongqing University, Chongqing, China.ORCID 0000-0001-5668-7567
Xingsheng WangDepartment of Respiratory Medicine, Chongqing Emergency Medical Center, Affiliated Central Hospital of Chongqing University, Chongqing, China.ORCID 0000-0002-8190-7506
Haibo WuSchool of Life Sciences, Chongqing University, Chongqing, China.ORCID 0000-0002-5961-2947
Chongqing University · CNChongqing Public Health Medical Center · CNGhent University · BEThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNUniversity of California, Berkeley · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that places a heavy strain on public health. Host susceptibility to Mtb is modulated by macrophages, which regulate the balance between cell apoptosis and necrosis. However, the role of molecular switches that modulate apoptosis and necrosis during Mtb infection remains unclear. Here, we show that Mtb-susceptible mice and TB patients have relatively low miR-342-3p expression, while mice with miR-342-3p overexpression are more resistant to Mtb. We demonstrate that the miR-342-3p/SOCS6 axis regulates anti-Mtb immunity by increasing the production of inflammatory cytokines and chemokines. Most importantly, the miR-342-3p/SOCS6 axis participates in the switching between Mtb-induced apoptosis and necrosis through A20-mediated K48-linked ubiquitination and RIPK3 degradation. Our findings reveal several strategies by which the host innate immune system controls intracellular Mtb growth via the miRNA-mRNA network and pave the way for host-directed therapies targeting these pathways.

Indexed as

MicroRNAsMycobacterium tuberculosisTuberculosisAnimalsCell DeathHumansInflammationMiceSuppressor of Cytokine Signaling ProteinsMicroRNAsMIRN342 microRNA, humanSOCS6 protein, humanSuppressor of Cytokine Signaling ProteinsapoptosisinflammationmicroRNAtuberculosisubiquitination

Identifiers

PMID34288348
PMCPMC8419689
OpenAlexW3183752025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.